About Transcriptional repressor protein YY1
Transcriptional repressor protein YY1 (YY1) is a protein
from Homo sapiens identified by UniProt accession
P25490, 414 residues long.
MolForge cross-references it against 0 known binders and
373 disease associations.
Target properties
| Protein name | Transcriptional repressor protein YY1 |
| UniProt accession | P25490 |
| Gene | YY1 |
| Organism | Homo sapiens |
| Length | 414 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (373)
Diseases linked to this target (Open Targets).
- Gabriele de Vries syndrome · score 0.76
- Intellectual disability · score 0.59
- genetic disorder · score 0.45
- Neurodevelopmental disorder · score 0.30
- glioblastoma multiforme · score 0.28
- neurodegenerative disease · score 0.27
- disease progression measurement · score 0.24
- metastasis measurement · score 0.24
- endometrial cancer · score 0.23
- low grade glioma · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P25490-F1 | alphafold | PREDICTED | 50.59 | — |
Amino-acid sequence (414 residues)
MASGDTLYIA TDGSEMPAEI VELHEIEVET IPVETIETTV VGEEEEEDDD DEDGGGGDHG GGGGHGHAGH HHHHHHHHHH PPMIALQPLV TDDPTQVHHH QEVILVQTRE EVVGGDDSDG LRAEDGFEDQ ILIPVPAPAG GDDDYIEQTL VTVAAAGKSG GGGSSSSGGG RVKKGGGKKS GKKSYLSGGA GAAGGGGADP GNKKWEQKQV QIKTLEGEFS VTMWSSDEKK DIDHETVVEE QIIGENSPPD YSEYMTGKKL PPGGIPGIDL SDPKQLAEFA RMKPRKIKED DAPRTIACPH KGCTKMFRDN SAMRKHLHTH GPRVHVCAEC GKAFVESSKL KRHQLVHTGE KPFQCTFEGC GKRFSLDFNL RTHVRIHTGD RPYVCPFDGC NKKFAQSTNL KSHILTHAKA KNNQ
Explore Transcriptional repressor protein YY1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets